Cargando…

Cellular Virotherapy Increases Tumor-Infiltrating Lymphocytes (TIL) and Decreases their PD-1(+) Subsets in Mouse Immunocompetent Models

Oncolytic virotherapy uses viruses designed to selectively replicate in cancer cells. An alternative to intratumoral administration is to use mesenchymal stem cells (MSCs) to transport the oncolytic viruses to the tumor site. Following this strategy, our group has already applied this treatment to c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morales-Molina, Alvaro, Rodríguez-Milla, Miguel Ángel, Gimenez-Sanchez, Alicia, Perisé-Barrios, Ana Judith, García-Castro, Javier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409201/ https://www.ncbi.nlm.nih.gov/pubmed/32708639 http://dx.doi.org/10.3390/cancers12071920

Ejemplares similares

Intracranial Virotherapy for a Canine Hemangioma
por: Delgado-Bonet, Pablo, et al.
Publicado: (2022)

Biodistribution Analysis of Oncolytic Adenoviruses in Canine Patient Necropsy Samples Treated with Cellular Virotherapy
por: Gómez, Ana, et al.
Publicado: (2020)

Expansion and Characterization of Human Melanoma Tumor-Infiltrating Lymphocytes (TILs)
por: Nguyen, Linh T., et al.
Publicado: (2010)

Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancer
por: Poch, Michael, et al.
Publicado: (2018)

Combining Analysis of Tumor-infiltrating Lymphocytes (TIL) and PD-L1 Refined the Prognostication of Breast Cancer Subtypes
por: Ni, Yunbi, et al.
Publicado: (2022)

Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases
por: Harter, Patrick N., et al.
Publicado: (2015)

Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors
por: Hall, MacLean, et al.
Publicado: (2016)

Synthetic TILs: Engineered Tumor-Infiltrating Lymphocytes With Improved Therapeutic Potential
por: Jiménez-Reinoso, Anaïs, et al.
Publicado: (2021)

Prognostic and Predictive Role of Tumor-Infiltrating Lymphocytes (TILs) in Ovarian Cancer
por: Fanale, Daniele, et al.
Publicado: (2022)

Expression of programmed cell death ligand 1 (PD-L1) and prevalence of tumor-infiltrating lymphocytes (TILs) in chordoma
por: Feng, Yong, et al.
Publicado: (2015)

The presence of tumour-infiltrating lymphocytes (TILs) and the ratios between different subsets serve as prognostic factors in advanced hypopharyngeal squamous cell carcinoma
por: Wang, Jie, et al.
Publicado: (2020)

Identification of neoepitopes recognized by tumor-infiltrating lymphocytes (TILs) from patients with glioma
por: Valentini, Davide, et al.
Publicado: (2018)

Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer
por: Kos, Zuzana, et al.
Publicado: (2020)

Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges
por: Zhao, Yueshui, et al.
Publicado: (2022)

PD-L1, CD4+, and CD8+ Tumor-Infiltrating Lymphocytes (TILs) Expression Profiles in Melanoma Tumor Microenvironment Cells
por: Caraban, Bogdan Marian, et al.
Publicado: (2023)

Correction: Identification of neoepitopes recognized by tumor-infiltrating lymphocytes (TILs) from patients with glioma
por: Valentini, Davide, et al.
Publicado: (2018)

Identification of the Tumor Infiltrating Lymphocytes (TILs) Landscape in Pure Squamous Cell Carcinoma of the Bladder
por: Eismann, Lennert, et al.
Publicado: (2022)

Tumor infiltrating lymphocytes (TILs) are a prognosis biomarker in Colombian patients with triple negative breast cancer
por: Huertas-Caro, Carlos A., et al.
Publicado: (2023)

Identification of biomarkers related to Tumor-Infiltrating Lymphocytes (TILs) infiltration with gene co-expression network in colorectal cancer
por: Liao, Rong, et al.
Publicado: (2021)

Correlation between cancer stem cells (CSCs) and tumor-infiltrating lymphocytes (TILs): do TILs interact with CSCs in non-small cell lung cancer?
por: Ling, Min, et al.
Publicado: (2020)

A phase I trial of repeated tumour-infiltrating lymphocyte (TIL) infusion in metastatic melanoma.
por: Ravaud, A., et al.
Publicado: (1995)

Use of Tumor-infiltrating lymphocytes (TILs) to predict the treatment response to eribulin chemotherapy in breast cancer
por: Kashiwagi, Shinichiro, et al.
Publicado: (2017)

Enhanced tumor-infiltrating lymphocytes (eTIL) for cellular therapy of patients with pancreatic cancer or glioblastoma
por: Meng, Qingda, et al.
Publicado: (2015)

The Relationship between Tumor-infiltrating Lymphocytes (TILs) and Nasopharyngeal Carcinoma (NPC): A Systematic Review
por: Prasetyo, Awal, et al.
Publicado: (2021)

Evaluation of tumor-infiltrating lymphocytes (TILs) in molecular subtypes of an Indian cohort of breast cancer patients
por: Vaid, Pooja M., et al.
Publicado: (2022)

Novel strategies to improve efficacy of treatment with tumor-infiltrating lymphocytes (TILs) for patients with solid cancers
por: Tas, Liselotte, et al.
Publicado: (2023)

Immunoexpression of PD-L1, CD4+ and CD8+ cell infiltrates and tumor-infiltrating lymphocytes (TILs) in the microenvironment of actinic cheilitis and lower lip squamous cell carcinoma
por: de Souza, Vinícius Gonçalves, et al.
Publicado: (2022)

Fewer tumour-specific PD-1(+)CD8(+) TILs in high-risk “Infiltrating” HPV(−) HNSCC
por: Xu, Ke, et al.
Publicado: (2020)

Clinical scale zinc finger nuclease (ZFN)-driven gene-editing of PD-1 in tumor infiltrating lymphocytes (TIL) for the potential treatment of metastatic melanoma
por: Beane, Joal D, et al.
Publicado: (2014)

Programmed death ligand 1 (PD-L1) in colon cancer and its interaction with budding and tumor-infiltrating lymphocytes (TILs) as tumor-host antagonists
por: Lang-Schwarz, Corinna, et al.
Publicado: (2021)

Tumor Infiltrating Lymphocytes (TILS) and PD-L1 Expression in Breast Cancer: A Review of Current Evidence and Prognostic Implications from Pathologist’s Perspective
por: Angelico, Giuseppe, et al.
Publicado: (2023)

Identification of predictive biomarker signatures in melanoma tumors associated with response to tumor-infiltrating lymphocyte (TIL) therapy
por: Chen, Jie Qing, et al.
Publicado: (2013)

Resident Memory-Like Tumor-Infiltrating Lymphocytes (TIL(RM)): Latest Players in the Immuno-Oncology Repertoire
por: Smazynski, Julian, et al.
Publicado: (2018)

Fas Ligand (FasL) in Association with Tumor-Infiltrating Lymphocytes (TILs) in Early Stage Cervical Cancer
por: Anggraeni, Tricia Dewi, et al.
Publicado: (2020)

TilGAN: GAN for Facilitating Tumor-Infiltrating Lymphocyte Pathology Image Synthesis With Improved Image Classification
por: SAHA, MONJOY, et al.
Publicado: (2021)

Tumor-Infiltrating Lymphocytes (TILs) in Epithelial Ovarian Cancer: Heterogeneity, Prognostic Impact, and Relationship with Immune Checkpoints
por: Hudry, Delphine, et al.
Publicado: (2022)

Clinical Meaning of Stromal Tumor Infiltrating Lymphocytes (sTIL) in Early Luminal B Breast Cancer
por: García-Torralba, Esmeralda, et al.
Publicado: (2023)

Virotherapy induces massive infiltration of neutrophils in a subset of tumors defined by a strong endogenous interferon response activity
por: Fu, Xinping, et al.
Publicado: (2011)

Lymphocyte activation gene-3 (LAG3) mRNA and protein expression on tumour infiltrating lymphocytes (TILs) in oesophageal adenocarcinoma
por: Gebauer, Florian, et al.
Publicado: (2020)

Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions
Publicado: (1996)

Cannot write session to /tmp/vufind_sessions/sess_8ucag85s6o67mmf6vtmo8hkrb1